203 related articles for article (PubMed ID: 30626852)
1. [Lenvatinib:new molecular targeted therapy of hepatocellular carcinoma -the progress and future perspective].
Kobayashi M
Nihon Shokakibyo Gakkai Zasshi; 2019; 116(1):36-44. PubMed ID: 30626852
[No Abstract] [Full Text] [Related]
2. Paraneoplastic Polyarthritis in Hepatocellular Carcinoma Treated With Lenvatinib.
Sathiyapalan A; Legault K; van der Pol CB; Meyers BM
Hepatology; 2021 Sep; 74(3):1705-1707. PubMed ID: 33709492
[No Abstract] [Full Text] [Related]
3. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?
Oikonomopoulos G; Aravind P; Sarker D
Future Oncol; 2016 Feb; 12(4):465-76. PubMed ID: 26785762
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib mesylate to treat hepatocellular carcinoma.
Ielasi L; Tovoli F; Piscaglia F
Drugs Today (Barc); 2019 May; 55(5):305-313. PubMed ID: 31131841
[TBL] [Abstract][Full Text] [Related]
5. Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma.
Hirooka M; Ochi H; Hiraoka A; Koizumi Y; Matsuura B; Joko K; Michitaka K; Abe M; Hiasa Y
Intern Med; 2019 Mar; 58(6):791-795. PubMed ID: 30333428
[TBL] [Abstract][Full Text] [Related]
6. [Experience of Treatment with Lenvatinib in Patients with Advanced HCC-A in a Single Institution].
Katsura Y; Takeda Y; Ohmura Y; Sakamoto T; Kawai K; Inatome J; Murakami K; Naito A; Kagawa Y; Masuzawa T; Takeno A; Hata T; Egawa C; Murata K
Gan To Kagaku Ryoho; 2019 Dec; 46(13):2101-2103. PubMed ID: 32157073
[TBL] [Abstract][Full Text] [Related]
7. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
Ikeda M; Kobayashi M; Tahara M; Kaneko S
Expert Opin Drug Saf; 2018 Nov; 17(11):1095-1105. PubMed ID: 30264594
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
Cai H; Zhang L; Li N; Zheng B; Liu M
J Comp Eff Res; 2020 Jun; 9(8):553-562. PubMed ID: 32419473
[No Abstract] [Full Text] [Related]
9. A spontaneous rupture of lung metastasis from hepatocellular carcinoma after the introduction of lenvatinib.
Higashino M; Sugiura R; Yamamoto Y; Naruse H; Sakamoto N
J Gastrointestin Liver Dis; 2021 Mar; 30(1):169-170. PubMed ID: 33723551
[No Abstract] [Full Text] [Related]
10. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
Kuorda H; Abe T; Fujiwara Y; Okamoto T; Yonezawa M; Sato H; Endo K; Oikawa T; Sawara K; Takikawa Y
World J Gastroenterol; 2019 May; 25(19):2365-2372. PubMed ID: 31148907
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
12. Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy.
Zhao Y; Zhang YN; Wang KT; Chen L
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188391. PubMed ID: 32659252
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome.
Fuchigami A; Imai Y; Uchida Y; Uchiya H; Fujii Y; Nakazawa M; Ando S; Sugawara K; Nakayama N; Tomiya T; Mochida S
PLoS One; 2020; 15(4):e0231427. PubMed ID: 32275701
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting.
Obi S; Sato T; Sato S; Kanda M; Tokudome Y; Kojima Y; Suzuki Y; Hosoda K; Kawai T; Kondo Y; Isomura Y; Ohyama H; Nakagomi K; Ashizawa H; Miura Y; Amano H; Mochizuki H; Omata M
Hepatol Int; 2019 Mar; 13(2):199-204. PubMed ID: 30671808
[TBL] [Abstract][Full Text] [Related]
15. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.
Kirino S; Tsuchiya K; Kurosaki M; Kaneko S; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Okada M; Wang W; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Izumi N
PLoS One; 2020; 15(4):e0231828. PubMed ID: 32310967
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib
Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
Anticancer Res; 2020 Apr; 40(4):2283-2290. PubMed ID: 32234927
[TBL] [Abstract][Full Text] [Related]
17. Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma.
Takahashi A; Moriguchi M; Seko Y; Ishikawa H; Yo T; Kimura H; Fujii H; Shima T; Mitsumoto Y; Ishiba H; Takashima H; Nagao Y; Jo M; Arai M; Hara T; Okajima A; Muramatsu A; Morita A; Yoshinami N; Nakajima T; Mitsuyoshi H; Umemura A; Nishikawa T; Yamaguchi K; Itoh Y
Anticancer Res; 2019 Sep; 39(9):5149-5156. PubMed ID: 31519627
[TBL] [Abstract][Full Text] [Related]
18. Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib.
Kodama K; Kawaoka T; Namba M; Uchikawa S; Ohya K; Morio K; Nakahara T; Murakami E; Yamauchi M; Hiramatsu A; Imamura M; Chayama K; Aikata H
Oncology; 2019; 97(2):75-81. PubMed ID: 31242488
[TBL] [Abstract][Full Text] [Related]
19. Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
Ikeda M; Okusaka T; Mitsunaga S; Ueno H; Tamai T; Suzuki T; Hayato S; Kadowaki T; Okita K; Kumada H
Clin Cancer Res; 2016 Mar; 22(6):1385-94. PubMed ID: 26500236
[TBL] [Abstract][Full Text] [Related]
20. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.
Hoshi T; Watanabe Miyano S; Watanabe H; Sonobe RMK; Seki Y; Ohta E; Nomoto K; Matsui J; Funahashi Y
Biochem Biophys Res Commun; 2019 May; 513(1):1-7. PubMed ID: 30944079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
